{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:45:17Z","timestamp":1794055517629,"version":"4.8.0"},"reference-count":70,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T00:00:00Z","timestamp":1648944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is the most dramatic pandemic of the new millennium; to counteract it, specific vaccines have been launched in record time under emergency use authorization or conditional marketing authorization by virtue of a favorable risk\/benefit balance. Among the various technological platforms, there is that exploiting a nucleoside-modified messenger RNA (modRNA), such as Comirnaty\u00ae, and that which is adenoviral vector-based. In the ongoing pharmacovigilance, the product information of the latter has been updated about the risk of thrombotic thrombocytopenia, venous thromboembolism without thrombocytopenia and immune thrombocytopenia without thrombosis. However, from an in-depth literature review, the same adverse events can rarely occur with modRNA vaccines too. In support of this, we here report a three-case series of thrombotic deaths in patients over 50 with comorbidities temporally after Comirnaty\u00ae, investigated by means of post-mortem histopathology and immunohistochemistry. In two out of three cases, the cause of death is traced back to pulmonary microthromboses rich in activated platelets, quite similar morphologically to those described in patients who died from severe COVID-19. Even if remote in the face of millions of administered doses, clinicians should be aware of the possible thrombotic risk also after Comirnaty\u00ae, in order to avoid a misdiagnosis with potentially lethal consequences. Since COVID-19 vaccines are inoculated in subjects to be protected, maximum attention must be paid to their safety, and prophylactic measures to increase it are always welcome. In light of the evidence, the product information of modRNA COVID-19 vaccines should be updated about the thrombotic risk, as happened for adenoviral vector-based vaccines.<\/jats:p>","DOI":"10.3390\/pathogens11040435","type":"journal-article","created":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T06:04:01Z","timestamp":1648965841000},"page":"435","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Three-Case Series of Thrombotic Deaths in Patients over 50 with Comorbidities Temporally after modRNA COVID-19 Vaccination"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-2216","authenticated-orcid":false,"given":"Luca","family":"Roncati","sequence":"first","affiliation":[{"name":"Institute of Pathology, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-9515","authenticated-orcid":false,"given":"Antonio","family":"Manenti","sequence":"additional","affiliation":[{"name":"Unit of Surgery, Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 41125 Modena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Corsi","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, 41125 Modena, Italy"},{"name":"National Institute of Biostructures and Biosystems, Inter-University Consortium, 00136 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1057\/s41271-021-00299-6","article-title":"Emergency use authorization (EUA), conditional marketing authorization (CMA), and the precautionary principle at the time of COVID-19 pandemic","volume":"42","author":"Roncati","year":"2021","journal-title":"J. Public Health Policy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Scully","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1469-7481","article-title":"Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: Guidance statement from the GTH","volume":"41","author":"Oldenburg","year":"2021","journal-title":"Hamostaseologie"},{"key":"ref_6","unstructured":"European Medicines Agency (2022, January 18). Vaxzevria (Previously COVID-19 Vaccine AstraZeneca): EPAR\u2014Product Information. Annex I\u2014Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf."},{"key":"ref_7","unstructured":"Norwegian Institute of Public Health (2021, April 15). Norwegian Institute of Public Health\u2019s Recommendation about AstraZeneca Vaccine, Available online: https:\/\/www.fhi.no\/en\/news\/2021\/astrazeneca-vaccine-removed-from-coronavirus-immunisation-programme-in-norw\/."},{"key":"ref_8","unstructured":"Danish Health Authority (2021, April 14). Denmark Continues Its Vaccine Rollout without the COVID-19 Vaccine from AstraZeneca, Available online: https:\/\/www.sst.dk\/en\/english\/news\/2021\/denmark-continues-its-vaccine-rollout-without-the-covid-19-vaccine-from-astrazeneca."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination","volume":"384","author":"Muir","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"America Society of Hematology (2022, January 28). COVID-19 Resources\u2014Vaccine-Induced Immune Thrombotic Thrombocytopenia. Available online: https:\/\/www.hematology.org\/covid-19\/vaccine-induced-immune-thrombotic-thrombocytopenia."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/jth.15362","article-title":"Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination","volume":"19","author":"Platton","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13665","article-title":"COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome","volume":"107","author":"Franchini","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.V76.2.336.336","article-title":"Structural and functional comparison of the genes for human platelet factor 4 and PF4alt","volume":"76","author":"Eisman","year":"1990","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMp068309","article-title":"Drug-induced immune-mediated thrombocytopenia\u2014From purpura to thrombosis","volume":"356","author":"Warkentin","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_15","unstructured":"European Medicines Agency (2022, January 20). COVID-19 Vaccine Janssen: EPAR\u2014Product Information. Annex I\u2014Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-janssen-epar-product-information_en.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1002\/jmv.26924","article-title":"Nucleoside-modified messenger RNA COVID-19 vaccine platform","volume":"93","author":"Roncati","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_17","unstructured":"European Medicines Agency (2022, January 20). Comirnaty: EPAR\u2014Product Information. Annex I\u2014Summary of Product Characteristics, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/comirnaty-epar-product-information_en.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"McKeigue, P.M., Burgul, R., Bishop, J., Robertson, C., McMenamin, J., O\u2019Leary, M., McAllister, D.A., and Colhoun, H.M. (2021). Association of cerebral venous thrombosis with recent COVID-19 vaccination: Case-crossover study using ascertainment through neuroimaging in Scotland. BMC Infect. Dis., 21.","DOI":"10.1186\/s12879-021-06960-5"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Finsterer, J., and Nics, S. (2021). Venous sinus thrombosis after the second jab of a mRNA-based SARS-CoV-2 vaccine. Brain Hemorrhages, in press.","DOI":"10.1016\/j.hest.2021.12.001"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10072-021-05714-0","article-title":"Cerebral venous sinus thrombosis after mRNA-based COVID-19 vaccination","volume":"43","author":"Yagi","year":"2022","journal-title":"Neurol. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3988\/jcn.2021.17.4.573","article-title":"Cerebral venous sinus thrombosis after Pfizer-BioNTech COVID-19 (BNT162b2) vaccination","volume":"17","author":"Cheng","year":"2021","journal-title":"J. Clin. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00701-021-04860-w","article-title":"Cerebral venous sinus thrombosis 2 weeks after the first dose of mRNA SARS-CoV-2 vaccine","volume":"163","author":"Zakaria","year":"2021","journal-title":"Acta Neurochir."},{"key":"ref_23","first-page":"e18775","article-title":"Cerebral venous sinus thrombosis after BNT162b2 mRNA COVID-19 vaccination","volume":"13","author":"Yamaguchi","year":"2021","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"E357","DOI":"10.1002\/ajh.26272","article-title":"Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event","volume":"96","author":"Fan","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105906","article-title":"Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine","volume":"30","author":"Dias","year":"2021","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_26","first-page":"e932946","article-title":"A 59-year-old woman with extensive deep vein thrombosis and pulmonary thromboembolism 7 days following a first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine","volume":"22","author":"Kashoub","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12185-021-03285-6","article-title":"Isolated thrombosis after COVID-19 vaccination: Case series","volume":"115","author":"Altourah","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"729251","DOI":"10.3389\/fimmu.2021.729251","article-title":"COVID-19 vaccine-related thrombosis: A systematic review and exploratory analysis","volume":"12","author":"Bilotta","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/jth.15493","article-title":"Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: Thrombosis at unusual sites","volume":"19","author":"Abbattista","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40545-021-00326-7","article-title":"Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)","volume":"14","author":"Shimazawa","year":"2021","journal-title":"J. Pharm. Policy Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40264-021-01138-z","article-title":"Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: The effect of publicity","volume":"45","author":"Ferner","year":"2022","journal-title":"Drug Saf."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IMCRJ.S328931","article-title":"Combined central retinal artery and vein occlusion with ischemic optic neuropathy after COVID-19 vaccination","volume":"15","author":"Lee","year":"2022","journal-title":"Int. Med. Case Rep. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e28236","DOI":"10.1097\/MD.0000000000028236","article-title":"Exacerbation of branch retinal vein occlusion post SARS-CoV-2 vaccination: Case reports","volume":"100","author":"Tanaka","year":"2021","journal-title":"Medicine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1016\/j.mayocp.2021.10.010","article-title":"mRNA COVID-19 vaccine-related anaphylactoid reaction and coronary thrombosis","volume":"96","author":"Hinton","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_35","first-page":"n1931","article-title":"Risk of thrombocytopenia and thromboembolism after COVID-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study","volume":"374","author":"Patone","year":"2021","journal-title":"BMJ"},{"key":"ref_36","first-page":"e18985","article-title":"A case of idiopathic thrombocytopenic purpura after booster dose of BNT162b2 (Pfizer-BioNtech) COVID-19 vaccine","volume":"13","author":"Malayala","year":"2021","journal-title":"Cureus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/jth.15418","article-title":"First report of a de novo iTTP episode associated with a mRNA-based anti-COVID-19 vaccination","volume":"19","author":"Maes","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"ref_38","first-page":"1688","article-title":"Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination","volume":"62","author":"Sato","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12185-021-03190-y","article-title":"Thrombotic thrombocytopenic purpura: A new menace after COVID BNT162b2 vaccine","volume":"114","author":"Waqar","year":"2021","journal-title":"Int. J. Hematol."},{"key":"ref_40","first-page":"1519","article-title":"Development of thrombocytopenic purpura following BNT162b2 mRNA COVID-19 vaccination","volume":"62","author":"Shibata","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"751598","DOI":"10.3389\/fmed.2021.751598","article-title":"Potential triggers for thrombocytopenia and\/or hemorrhage by the BNT162b2 vaccine, Pfizer-BioNTech","volume":"8","author":"Okada","year":"2021","journal-title":"Front. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1111\/1759-7714.14179","article-title":"Lung squamous cell carcinoma with hemoptysis after vaccination with tozinameran (BNT162b2, Pfizer-BioNTech)","volume":"12","author":"Sumi","year":"2021","journal-title":"Thorac. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e242220","DOI":"10.1136\/bcr-2021-242220","article-title":"Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination","volume":"14","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/ajh.26132","article-title":"Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination","volume":"96","author":"Lee","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.21037\/atm-21-2772","article-title":"An unusual presentation of acute deep vein thrombosis after the Moderna COVID-19 vaccine\u2014A case report","volume":"9","author":"Bhan","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"772424","DOI":"10.3389\/fmed.2021.772424","article-title":"Case report: Vaccine-induced immune thrombotic thrombocytopenia in a pancreatic cancer patient after vaccination with messenger RNA-1273","volume":"8","author":"Su","year":"2021","journal-title":"Front. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e933397","DOI":"10.12659\/AJCR.933397","article-title":"Central venous sinus thrombosis with subarachnoid hemorrhage following a mRNA COVID-19 vaccination: Are these reports merely co-incidental?","volume":"22","author":"Syed","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jvsv.2021.07.009","article-title":"Three cases of acute venous thromboembolism in females after vaccination for coronavirus disease 2019","volume":"10","author":"Andraska","year":"2022","journal-title":"J. Vasc. Surg. Venous Lymphat. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.7326\/M21-2680","article-title":"Thrombosis after vaccination with messenger RNA-1273: Is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome?","volume":"174","author":"Pishko","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Osmanodja, B., Schreiber, A., Schrezenmeier, E., and Seelow, E. (2021). First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine\u2014Case report. BMC Nephrol., 22.","DOI":"10.1186\/s12882-021-02616-3"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2100956","DOI":"10.1183\/13993003.00956-2021","article-title":"Vaccination against COVID-19: Insight from arterial and venous thrombosis occurrence using data from VigiBase","volume":"58","author":"Smadja","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Favaloro, E.J., Pasalic, L., and Lippi, G. (2022). Antibodies against platelet factor 4 and their associated pathologies: From HIT\/HITT to spontaneous HIT-like syndrome, to COVID-19, to VITT\/TTS. Antibodies, 11.","DOI":"10.3390\/antib11010007"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood.2021012217","article-title":"Frequency of positive anti-PF4\/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2","volume":"138","author":"Thiele","year":"2021","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"See, I., Lale, A., Marquez, P., Streiff, M.B., Wheeler, A.P., Tepper, N.K., Woo, E.J., Broder, K.R., Edwards, K.M., and Gallego, R. (2022). Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021. Ann. Intern. Med., in press.","DOI":"10.7326\/M21-4502"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2021014214","article-title":"Most anti-PF4 antibodies in vaccine-induced immune thrombotic thrombocytopenia are transient","volume":"139","author":"Thiele","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Ueland, T., Hausberg, I., M\u00f8rtberg, T.V., Dahl, T.B., Lerum, T.V., Michelsen, A., Ranheim, T., Nezvalova Henriksen, K., Dyrhol-Riise, A.M., and Holme, P.A. (2022). Anti-PF4\/polyanion antibodies in COVID-19 patients are associated with disease severity and pulmonary pathology. Platelets, in press.","DOI":"10.1080\/09537104.2022.2042238"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1080\/09537104.2020.1810224","article-title":"A proof of evidence supporting abnormal immunothrombosis in severe COVID-19: Naked megakaryocyte nuclei increase in the bone marrow and lungs of critically ill patients","volume":"31","author":"Roncati","year":"2020","journal-title":"Platelets"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11239-021-02444-0","article-title":"Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson\u2019s syndrome","volume":"52","author":"Roncati","year":"2021","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_59","first-page":"e14726","article-title":"SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation","volume":"9","year":"2021","journal-title":"Physiol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1055\/s-0040-1721733","article-title":"Autoimmune hemolytic anemia and pulmonary embolism: An association to consider","volume":"5","author":"Solari","year":"2021","journal-title":"TH Open"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.thromres.2015.09.004","article-title":"Autoimmune hemolytic anemia and venous thromboembolism: A systematic review and meta-analysis","volume":"136","author":"Ungprasert","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"bcr2012007351","DOI":"10.1136\/bcr-2012-007351","article-title":"Tacrolimus-associated thrombotic microangiopathy in a lung transplant recipient","volume":"2013","author":"Boyer","year":"2013","journal-title":"BMJ Case Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00467-014-3036-8","article-title":"De novo tacrolimus-induced thrombotic microangiopathy in the early stage after renal transplantation successfully treated with conversion to everolimus","volume":"30","author":"Cortina","year":"2015","journal-title":"Pediatr. Nephrol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1681\/ASN.2007030308","article-title":"Chronic kidney disease increases risk for venous thromboembolism","volume":"19","author":"Wattanakit","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCP.0b013e32832ee371","article-title":"Chronic kidney disease and venous thromboembolism: Epidemiology and mechanisms","volume":"15","author":"Wattanakit","year":"2009","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mathieson, P., Reckless, I., and Ferrett, C. (2012). Secondary spontaneous pneumothorax: A rare complication of pulmonary embolism. BMJ Case Rep., 2012.","DOI":"10.1136\/bcr-2012-006860"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.athoracsur.2021.03.009","article-title":"Deepening pathology of SARS-CoV-2 pneumonia explains lung ventilation complications","volume":"113","author":"Manenti","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"ref_68","unstructured":"United States Centers for Disease Control and Prevention (2022, February 14). Safety of COVID-19 Vaccines, Available online: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/safety-of-vaccines.html."},{"key":"ref_69","unstructured":"European Medicines Agency (2022, February 17). COVID-19 Vaccines Safety Update, Available online: https:\/\/www.ema.europa.eu\/en\/documents\/covid-19-vaccine-safety-update\/covid-19-vaccines-safety-update-17-february-2022_en.pdf."},{"key":"ref_70","unstructured":"Agenzia Italiana del Farmaco (2022, February 11). Rapporto Annuale Sulla Sicurezza Dei Vaccini Anti-COVID-19, Available online: https:\/\/www.aifa.gov.it\/documents\/20142\/1315190\/Rapporto_annuale_su_sicurezza_vaccini%20anti-COVID-19.pdf."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/4\/435\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:49:20Z","timestamp":1760136560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/4\/435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,3]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pathogens11040435"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11040435","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,3]]}}}